JP2025504706A - 運動機能を改善する方法および組成物 - Google Patents

運動機能を改善する方法および組成物 Download PDF

Info

Publication number
JP2025504706A
JP2025504706A JP2024537409A JP2024537409A JP2025504706A JP 2025504706 A JP2025504706 A JP 2025504706A JP 2024537409 A JP2024537409 A JP 2024537409A JP 2024537409 A JP2024537409 A JP 2024537409A JP 2025504706 A JP2025504706 A JP 2025504706A
Authority
JP
Japan
Prior art keywords
fontan
udenafil
patients
patient
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024537409A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025504706A5 (https=
Inventor
イェーガー，ジェームズ，エル．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2025504706A publication Critical patent/JP2025504706A/ja
Publication of JP2025504706A5 publication Critical patent/JP2025504706A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2024537409A 2021-12-20 2022-12-20 運動機能を改善する方法および組成物 Pending JP2025504706A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163291858P 2021-12-20 2021-12-20
US63/291,858 2021-12-20
PCT/US2022/000033 WO2023121689A1 (en) 2021-12-20 2022-12-20 Methods and compositions for improving exercise performance

Publications (2)

Publication Number Publication Date
JP2025504706A true JP2025504706A (ja) 2025-02-17
JP2025504706A5 JP2025504706A5 (https=) 2025-12-22

Family

ID=85382567

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024537409A Pending JP2025504706A (ja) 2021-12-20 2022-12-20 運動機能を改善する方法および組成物

Country Status (8)

Country Link
US (1) US20240285630A1 (https=)
EP (1) EP4452273A1 (https=)
JP (1) JP2025504706A (https=)
CN (1) CN119072312A (https=)
AU (1) AU2022419178A1 (https=)
CA (1) CA3243958A1 (https=)
MX (1) MX2024007796A (https=)
WO (1) WO2023121689A1 (https=)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TN2017000029A1 (en) 2014-08-12 2018-07-04 Mezzion Pharma Co Ltd Methods of improving myocardial performance in fontan patients using udenafil compositions
AU2020356193A1 (en) * 2019-09-24 2022-05-19 Children's Hospital Of Philadelphia Methods of improving exercise performance, single ventricular performance, and myocardial performance index (MPI) in single ventricle heart disease, using udenafil compositions

Also Published As

Publication number Publication date
MX2024007796A (es) 2025-04-02
CA3243958A1 (en) 2023-06-29
EP4452273A1 (en) 2024-10-30
US20240285630A1 (en) 2024-08-29
CN119072312A (zh) 2024-12-03
AU2022419178A1 (en) 2024-08-08
WO2023121689A1 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
Guazzi et al. Long-term use of sildenafil in the therapeutic management of heart failure
US20250186448A1 (en) Formulations of udenafil
JP2024020187A (ja) ウデナフィル組成物を用いてフォンタン患者における心筋性能を改善する方法
JP2025118624A (ja) ウデナフィル組成物を用いた単心室心疾患における運動能力、単心室性能、および心筋性能指数（ｍｐｉ）を改善する方法
JP2025504706A (ja) 運動機能を改善する方法および組成物
Goldberg et al. Results of the Fontan Udenafil exercise longitudinal (FUEL) trial

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251212

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251212